Progesterone Receptor Negative Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs